Body mass index and risk of nonalcoholic fatty liver disease: Two electronic health record prospective studies

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 3, 2016, Pages 945-952

  Katrina Loomis, A ^a,b   Kabadi, Shaum ^a,b   Preiss, David ^c   Hyde, Craig ^a,b   Bonato, Vinicius ^a   Louis, Matthew St ^a,b   Desai, Jigar ^a,b   Gill, Jason M R ^c   Welsh, Paul ^c   Waterworth, Dawn ^d   Sattar, Naveed ^c  

^a PFIZER INC   (United States)

^b Clinical Operations PfizerWorldwide Research and Development   (United States)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BODY MASS; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; SMOKING; DIABETES COMPLICATIONS; ELECTRONIC HEALTH RECORD; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE;

ADULT; BODY MASS INDEX; DIABETES COMPLICATIONS; ELECTRONIC HEALTH RECORDS; FEMALE; HUMANS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; SMOKING;

EID: 84960849887     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-3444     Document Type: Article

References (25)

1. Marchesini G, Moscatiello S, Di Domizio S, Forlani G. Obesity-associated liver disease. J Clin Endocrinol Metab. 2008;93(11 Suppl 1):S74-S80.
2. Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gas-troenterol. 2014;5:211-218.
3. Williams R, Aspinall R, Bellis M, et al. Addressing liver diseaseinthe UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet. 2014;384:1953-1997.
4. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005-2023.
5. Leite NC, Salles GF, Araujo ALE, Villela-Nogueira CA, Cardoso CRL. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 2009, 29: 113-119.
6. Gaidos JK, Hillner BE, Sanyal AJ. A decision analysis study of the value of a liver biopsy in nonalcoholic steatohepatitis. Liver Int. 2008;28:650-658.
7. Xu C, Yu C, Ma H, Xu L, Miao M, Li Y. Prevalence and risk factors for the development of nonalcoholic fatty liver disease in anonobese Chinese population: the Zhejiang Zhenhai Study. Am J Gastroen-terol. 2013;108:1299-1304.
8. Liu B, Balkwill A, Reeves G, Beral V. Body mass index and risk of liver cirrhosis in middle aged UK women: prospective study. BMJ. 2010;340:c912.
9. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitusinwomen. Ann Intern Med. 1995;122:481-486.
10. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care. 1994;17:961-969.
11. Sattar N, Gill JMR. Type 2 diabetes as a disease of ectopic fat? BMC Med. 2014;12:123.
12. Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol. 2012;56:255-266.
13. Lim EL, Hollingsworth KG, Aribisala BS, et al. Reversal of type 2 diabetes: normalisation of β cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia. 2011;54: 2506-2514.
14. Blak BT, Thompson M, Dattani H, Bourke A. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care. 2011;19:251-255.
15. Health Survey for England 2013. Health and social care information centre. Published December 2013. Available from www.hscic.g-ov.uk/pubs/hse2012.
16. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity among adults: United States, 2011-2012. JAMA. 2014;311:806-814.
17. Pan JJ, Fallon MB. Gender and racial differences in nonalcoholic fatty liver disease. World J Hepatol. 2014;6:274-283.
18. Younossi ZM, Stepanova M, Negro F, et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore). 2012;91;319-327.
19. Sattar N, Forrest E, Preiss D. Non-alcoholic fatty liver disease. BMJ. 2014;349:g4596.
20. Logue J, Walker JJ, Colhoun HM, et al. Do men develop type 2 diabetes at lower body mass indices than women? Diabetologia. 2011;54:3003-3006.
21. Schneider ALC, Lazo M, Selvin E, Clark JM. Racial differences in nonalcoholic fatty liver disease in the U.S. population. Obesity (Silver Spring). 2014;22:292-299.
22. Lawlor DA, Callaway M, Macdonald-Wallis C, et al. Nonalcoholic fatty liver disease, liver fibrosis, and cardiometabolic risk factors in adolescence: a cross-sectional study of 1874 general population adolescents. J Clin Endocrinol Metab. 2014;99:E410-E417.
23. Dyson J, Day C. Treatment of non-alcoholic fatty liver disease. Dig Dis. 2014;32:597-604.
24. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes. 2005;54:603-608.
25. Alazawi W, Mathur R, Abeysekera K, et al. Ethnicity and the diagnosis gap in liver disease: a population-based study. Br J Gen Pract. 2014;64:e694-e702.